Synthesis, characterization of novel N‐(4‐cyano‐1,3‐oxazol‐5‐yl)sulfonamide derivatives and in vitro screening their activity against NCI‐60 cancer cell lines

Abstract

AbstractA novel series of N‐(4‐cyano‐1,3‐oxazol‐5‐yl)sulfonamides have been synthesized and characterized by IR, 1H NMR, 13C NMR spectroscopy, elemental analysis and chromato‐mass‐spectrometry. The anticancer activities of all newly synthesized compounds were evaluated via a single high‐dose assay (10 μM) against 60 cancer cell lines by the National Cancer Institute (USA) according to its screening protocol. Among them, compounds 2 and 10 exhibited the highest activity against the 60 cancer cell lines panel in the one‐dose assay. Compounds 2 and 10 showed inhibitory activity within the GI50 parameter and in five dose analyses. However, their cytostatic activity was only observed against some cancer cell lines, and cytotoxic concentration was outside the maximum used, i. e., >100 μM. The COMPARE analysis showed that the average graphs of the tested compounds have a moderate positive correlation with compounds with the L‐cysteine analog and vinblastine (GI50) as well as paclitaxel (TGI), which target microtubules. Therefore, disruption of microtubule formation may be one of the mechanisms of the anticancer activity of the tested compounds, especially since among tubulin inhibitors with antitumor activity, compounds with an oxazole motif are widely represented. Therefore, N‐(4‐cyano‐1,3‐oxazol‐5‐yl)sulfonamides may be promising for further functionalization to obtain more active compounds.